ACHIEVE LIFE SCIENCES, INC.
Company Information
Industry In Vitro & In Vivo Diagnostic Substances
SIC Code 2835
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 22722 29TH DR. SE, SEATTLE, WA, 98021
Mailing Address 22722 29TH DR. SE, SEATTLE, WA, 98021
Phone 425-686-1500
Fiscal Year End 1231
EIN 954343413
Financial Overview
FY2025
-$29.82M
Net Income
$41.79M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 24, 2026 | View on SEC |
| 8-K Current report of material events | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 29, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | January 23, 2026 | View on SEC |
Annual Reports
10-K March 24, 2026
- Advancing cytisinicline as a novel treatment for smoking and vaping cessation.
- Secured $40 million in capital via stock sale and a $125 million loan facility.
Related Companies
Companies in the same industry (SIC: 2835)
IMMUCELL CORP /DE/
ICCC In Vitro & In Vivo Diagnostic Substances
Insight Molecular Diagnostics Inc.
IMDX In Vitro & In Vivo Diagnostic Substances
Q/C TECHNOLOGIES, INC.
QCLS In Vitro & In Vivo Diagnostic Substances
Cardio Diagnostics Holdings, Inc.
CDIO In Vitro & In Vivo Diagnostic Substances
MYRIAD GENETICS INC
MYGN In Vitro & In Vivo Diagnostic Substances
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.